Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

Jean M Whaley1 Bristol-Myers Squibb, Metabolic Disease Discovery Biology, Research and Development, Princeton, NJ, USACorrespondence[email protected]

Mark Tirmenstein2 Bristol-Myers Squibb, Drug Safety Evaluation, Research and Development, New Brunswick and Princeton, NJ, USA

Timothy P Reilly2 Bristol-Myers Squibb, Drug Safety Evaluation, Research and Development, New Brunswick and Princeton, NJ, USA

Simon M Poucher3 AstraZeneca, Cardiovascular and Gastrointestinal Innovative Medicines Science Unit, Alderley Park, Macclesfield, Cheshire, UK

JoAnne Saye4 AstraZeneca, Global Safety Assessment, Research and Development, Wilmington, DE, USA

Shamik Parikh5 AstraZeneca, Cardiovascular, Clinical Development, Wilmington, DE, USA

James F List6 Bristol-Myers Squibb, Global Clinical Development, Research and Development, Princeton, NJ, USA

Your download is now in progress and you may close this window